This article reviews the results of a mulitcenter trial evaluating the efficacy and safety of the injectable bulking agent Zuidex to treat intrinsic sphincter deficiency (ISD). This injectable agent showed promise in initial European trials; however, the results from this study were not equally positive. In fact, the results of this study have resulted in the makers of this drug not seeking Food and Drug Administration approval for its use in the United States.
展开▼
